Publication | Closed Access

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

Glucagon Receptor AgonistG Protein-coupled ReceptorMedicineDiabetesType 2PharmacotherapyNovel Triple GipDiabetes MellitusPharmacology